Literature DB >> 22245897

High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis.

Sven Pischke1, Juliane Gösling, Ilka Engelmann, Jerome Schlue, Benno Wölk, Elmar Jäckel, Christoph Meyer-Heithuis, Ulrich Lehmann, Christian P Strassburg, Hannelore Barg-Hock, Thomas Becker, Michael P Manns, Thomas Schulz, Heiner Wedemeyer, Albert Heim.   

Abstract

BACKGROUND & AIMS: In liver transplant recipients with graft hepatitis, the relevance of herpesviruses is not well defined.
METHODS: Viral loads of CMV, EBV, and HHV-6 were determined in blood and liver biopsies of 170 liver transplant recipients with graft hepatitis by quantitative PCR.
RESULTS: HHV-6-, CMV-, and EBV-DNA were detected in 58%, 14%, and 44% of the biopsies, respectively, with coinfections in 34%. High intrahepatic HHV-6 DNA levels (>75th percentile, 11.27 copies/1000 cells) and detection of HHV-6 DNAemia were significantly associated with decreased graft survival after diagnosis of graft hepatitis (p=0.014 and p=0.003, respectively, median follow-up was 23.8 months). Multivariate analysis confirmed high intrahepatic HHV-6 loads as an independent factor associated with reduced graft survival (adjusted hazard ratio 2.61, 95%confidence interval 1.16-5.87). Low concentrations of HHV6 DNA in the liver, indicating latent infection, did not influence graft survival. Neither CMV nor EBV (qualitative detection and high virus loads) nor acute rejection (according to the BANFF score) affected graft survival. However, patients had been treated for CMV reactivations and acute rejections in this retrospective study. High age and high bilirubin levels were the other independent factors associated with reduced graft survival (adjusted hazard ratio 3.56CI 1.52-8.34 and 3.23CI 1.50-6.96, respectively).
CONCLUSIONS: High intrahepatic HHV-6-DNA levels are associated with decreased graft survival in liver transplant recipients with graft hepatitis. The significance of HHV-6 as potential etiology of graft hepatitis needs further evaluation. Copyright Â
© 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22245897     DOI: 10.1016/j.jhep.2011.12.017

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

Review 1.  Past, present, and future perspectives on the diagnosis of Roseolovirus infections.

Authors:  Joshua A Hill; Ruth Hall Sedlak; Keith R Jerome
Journal:  Curr Opin Virol       Date:  2014-10-14       Impact factor: 7.090

Review 2.  Roseoloviruses in transplant recipients: clinical consequences and prospects for treatment and prevention trials.

Authors:  Joshua A Hill; Danielle M Zerr
Journal:  Curr Opin Virol       Date:  2014-10-04       Impact factor: 7.090

Review 3.  Advances in the Characterization of the T-Cell Response to Human Herpesvirus-6.

Authors:  Derek J Hanson; Joshua A Hill; David M Koelle
Journal:  Front Immunol       Date:  2018-06-25       Impact factor: 7.561

Review 4.  Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes.

Authors:  Gail E Reid; Joseph P Lynch; Samuel Weigt; David Sayah; John A Belperio; Shellee A Grim; Nina M Clark
Journal:  Semin Respir Crit Care Med       Date:  2016-08-03       Impact factor: 3.119

5.  Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Tuan L Phan; Kristen Carlin; Per Ljungman; Ioannis Politikos; Vicki Boussiotis; Michael Boeckh; Michele L Shaffer; Danielle M Zerr
Journal:  Biol Blood Marrow Transplant       Date:  2018-04-21       Impact factor: 5.742

6.  Human herpesvirus-6 and cytomegalovirus DNA in liver donor biopsies and their correlation with HLA matches and acute cellular rejection.

Authors:  Ana Carolina Guardia; Raquel Silveira Bello Stucchi; Arlete Milan; Sandra Cecília Botelho Costa; Ilka de Fátima Santana Ferreira Boin
Journal:  Braz J Infect Dis       Date:  2013-11-22       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.